Australia TGA approves tafasitamab combo in relapsed, refractory FL
The phase 3 inMIND trial evaluated the efficacy and safety of tafasitamab in combination with rituximab and lenalidomide in adult patients with relapsed
The phase 3 inMIND trial evaluated the efficacy and safety of tafasitamab in combination with rituximab and lenalidomide in adult patients with relapsed
Accord BioPharma, the therapy's manufacturer, expects a permanent Q-code from the US Centers for Medicare & Medicaid Services.
As we approach the end of the first quarter of 2026, I am pleased to share a brief update on the exceptional successes
In this video interview from SOHO Asia 2026, Dr. Feng-Ming Tien discusses the critical link between the immune microenvironment and therapeutic success in
The clearance allows the expansion of an international, phase 3 trial (CT103AC004) into Japan. This multi-center study evaluates the efficacy and safety of
The retrospective, single-center cohort study used linked data from the Princess Margaret Cancer Centre lymphoma database.
Registration is now officially open for the Fourteenth Annual Meeting of the Society of Hematologic Oncology. The event is scheduled for September 9
Live session held on March 18, 2026, from 2:30 – 3 pm CT with speaker Jeffrey Matous presenting on "Managing access to novel
The second session of the Community Oncology Brown Bag Series hosted by SOHO Insider featured guest speaker Tara Graff, DO, an oncologist at
The European Commission (EC) has approved nivolumab (Opdivo®) in combination with brentuximab vedotin for the treatment of adult and pediatric patients with relapsed